Why SANBio for sb623?
Having the world’s top-level development team is one of SanBio’s Strengths. As a global leader in regenerative cell medicine, SanBio works to develop pharmaceuticals, such as SB623, that can be delivered to patients all over the world.
What is SANBio's business model?
SanBio aims to deliver medical care to as many patients as possible. To produce large quantities of homogenous products from living cells, knowledge and expertise about cells, as well as time and perseverance are required. SanBio invested roughly 10 years in becoming successful in scaling up its production of drugs made with living cells.
Who is in charge of R&D and production at SANBio?
Bijan Nejadnik, M.D., Mohammad El-Kalay, Ph.D., and Haruhiko Tsumura, Ph.D., are in charge of the R&D and Production Department, respectively. Having the world’s top-level development team is one of SanBio’s Strengths.
What is SANBio's approach to regenerative cell medicine?
SanBio’s regenerative cell medicine employs allogeneic transplantation. Compared to the laborious, time-consuming, and costly process of autologous transplantation, it is possible to produce large quantities of homogenous products at lower costs. SanBio aims to deliver medical care to as many patients as possible.
What is SanBio regenerative medicine?
What is SB623?
SanBio’s regenerative cell medicine employs allogeneic transplantation. Compared to the laborious, time-consuming, and costly process of autologous transplantation, it is possible to produce large quantities of homogenous products at lower costs. SanBio aims to deliver medical care to as many patients as possible.
